Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of sIPV Co-administered With MMR and HepA-I.

NCT06442449 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT06442449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06442449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of sIPV Co-administered With MMR and HepA-I.
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 4
Overall status
Completed
Start date
August 8, 2024
Completion date
October 10, 2025
Enrollment
889 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis